Records how SGLT2 inhibitor medicines are used in adults with congenital heart disease
Studies safety and effects of SGLT2 inhibitor medicines in adults with congenital heart disease.
Key facts
- Who runs it
- Leiden University Medical Center
- Where
- Skopje, North MacedoniaSee the siteAlso in 4 other countries, 10 sites
- Trial code
- Registry title
- Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
- Status
- Recruiting
- People taking part
- 400 people, planned
- Started
- 1 Jan 2023
- Expected to end
- 31 Dec 2027
- Type of study
- Observational
- Treatments tested
- SGLT2 inhibitors
- Record updated
- 13 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The registry is looking for adults born with a heart defect who have started treatment with an SGLT2 inhibitor.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- A congenital heart defect (a heart problem present from birth).
- Earlier treatment
- Must have started treatment with an SGLT2i.
Main reasons for not taking part
- No consent for data collection
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Congenital heart defect
- Age ≥ 18 years
- Initiated on treatment with an SGLT2i
Who cannot take part
- No consent for data collection
Where in North Macedonia
Also in 4 other countries, 10 sites
- Zan Mitrev ClinicSkopje, North MacedoniaContact: Milka Klinceva, MD PhD (principal investigator)Taking people
About the trial
What the trial wants to find out
This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.
The group in the trial
- ACHD patients treated with SGLT2i
All participants included in the registry have to have a congenital heart defect, be ≥ 18 years old, and receive (or have received) treatment with SGLT2i.
Treatment: SGLT2 inhibitors
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i (ACHIEVE-SGLT2i) Registry
- Plain-language title
- Records how SGLT2 inhibitor medicines are used in adults with congenital heart diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Real-world experience with sodium-glucose cotransporter 2 inhibitors in adults with Fontan circulatory failure.Frontiers in cardiovascular medicine, 2026
- Record updated
- 13 February 2026